Beta

Clearmind medicine inc.CMND.US Overview

US StockHealthcare
(No presentation for CMND)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

CMND AI Insights

CMND Overall Performance

CMND AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CMND Recent Performance

0.96%

Clearmind medicine inc.

-1.10%

Avg of Sector

-0.49%

S&P500

CMND PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check CMND's Trend

CMND Key Information

CMND Valuation Metrics

CMND Profile

Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Price of CMND

CMND FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CMND Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-48.59
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.24
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
25.99%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-48.59
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.24
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
25.99%

  • When is CMND's latest earnings report released?

    The most recent financial report for Clearmind medicine inc. (CMND) covers the period of 2026Q1 and was published on 2026/01/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CMND's short-term business performance and financial health. For the latest updates on CMND's earnings releases, visit this page regularly.

  • How much cash does CMND have?

    At the end of the period, Clearmind medicine inc. (CMND) held Total Cash and Cash Equivalents of 9.26M, accounting for 0.83 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is CMND's EPS continuing to grow?

    According to the past four quarterly reports, Clearmind medicine inc. (CMND)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -3.32. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CMND?

    Clearmind medicine inc. (CMND)'s Free Cash Flow (FCF) for the period is -2.08M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 64.76% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of CMND?

    The latest valuation data shows Clearmind medicine inc. (CMND) has a Price-To-Earnings (PE) ratio of -0.19 and a Price/Earnings-To-Growth (PEG) ratio of 0.01. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.